Neuphoria Therapeutics Reports Q2 2026 Financial Results with $1.9M Net Income Turnaround

Neuphoria Therapeutics Inc. reported its financial results for the second quarter of fiscal year 2026, revealing a net income of $1.9 million for the three months ended December 31, 2025, a significant turnaround from a net loss of $1.9 million in the same period of the previous year. However, for the six months ended December 31, 2025, the company incurred a net loss of $8.0 million, compared to a loss of $2.7 million for the same period in 2024. The company did not generate any revenue during the latest quarter, a decrease attributed to the absence of milestone payments from licensing agreements, which had previously contributed to revenue.

Operating expenses for the quarter totaled $4.1 million, down from $4.4 million in the prior year, primarily due to reduced research and development costs, which fell by 60% to $0.7 million. This reduction reflects the company's strategic decision to pause its research and development activities while it seeks potential partnerships or mergers. General and administrative expenses also decreased by 19% to $2.1 million, driven by lower headcount costs. The company incurred restructuring costs of $1.2 million during the quarter, primarily related to employee terminations and facility lease terminations.

Neuphoria's total assets increased to $36.6 million as of December 31, 2025, up from $28.6 million at the end of June 2025. This growth was largely due to a rise in cash and cash equivalents, which reached $22.2 million, compared to $14.2 million at the end of the previous fiscal year. The company’s liabilities decreased significantly from $9.6 million to $6.9 million, reflecting a reduction in accounts payable and accrued expenses. The company’s accumulated deficit stood at $186.4 million, indicating ongoing challenges in achieving profitability.

In terms of strategic developments, Neuphoria has paused its lead product candidate, BNC210, for the treatment of post-traumatic stress disorder (PTSD) following the discontinuation of its social anxiety disorder program after the AFFIRM-1 Phase 3 trial did not meet its primary endpoint. The company is currently engaged in a strategic review process to explore potential partnerships or mergers to enhance shareholder value. Additionally, Neuphoria has implemented a shareholder rights plan to protect against potential hostile takeovers, which was triggered by significant stock accumulations by certain investors.

Looking ahead, Neuphoria anticipates continued net losses as it navigates its strategic review and seeks to identify a partner for its product candidates. The company believes its existing cash reserves will be sufficient to fund operations through the third quarter of fiscal year 2027. However, it remains uncertain whether it will achieve profitability or successfully commercialize its product candidates in the future.